Pharma and Patient Advocacy Groups Patient Centricity Finally Pays Off for Both
“Patient Centricity’ is finally paying off for drug companies in a BIG way, but it has nothing to do with designing clinical trials or marketing, both of which could claim to have been patient centric for many years.
The big patient-centricity payoff for pharma is its relationship with patient advocacy groups that are recruited to lobby Congress, local governments and the FDA to support industry-friendly legislation (or defeat anti-industry legislation) and influence the FDA drug approval process.
- The Yin Yang of Patient Advocate Groups and the Pharma Industry
- Mobile-Enabled Patient Focus Groups
- FDA May Establish “Office of Patient Affairs” to Capture Patient Perspectives
- The New, Patient-Centric FDA: A Double-edged Sword
- How Patient Advocates Make Money from Pharma with Help from Agents
- #Pharma Turning Patients With Rare Diseases Into D.C. Lobbyists
- 93% of Patient Advocacy Groups Included in FDA Funding Discussions Receive $ from Pharma
- More Than Two-thirds of Patient Advocacy Groups Receive Industry Funding
- Pharma’s Rep Among Patient Groups Sinks to Near Historical Lows
- Patient Advocate Backlash Against TV Drug Ads
Download the full article (PDF file) here:
- Is “Patient-Centric” Just Another Pharma Marketing Buzzword?
- Pharma’s Patient Centricity Pays Off: Patient Groups Mum on Drug Costs
- Anne Beale – one of the first Chief Patient Officer in Pharma – Discusses The Three Pillars of Sanofi’s Patient-Centric Strategy
- Novartis Respects the Patient Perspective and Pays for It Too
- Patients’ Views Matter: Can Pharma Be There for Them When Needed vs Whenever?
- Are Pharma Marketers Really Responsible for Patient Centricity/Engagement?
Issue: Vol. 16, No. 2: May 2017